Navigation Links
Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting

AAD Launches include New Technologies, Innovative Applications and New Clinical Data

SAN FRANCISCO, March 5 /PRNewswire/ -- Aesthera today announced several new launches at the upcoming 67th annual meeting of the American Academy of Dermatology in San Francisco, CA. Aligned with the company's strategic imperative to stay at the forefront of innovations in skin management, the launches will focus on the company reinforcing its leadership as the premier device based solution for acne as well as the development and commercialization of innovative technological solutions for high demand patient procedures.

Strengthening Position as Leading Acne Treatment

Strengthening its leadership position as a premier treatment in the battle against acne, Aesthera announced its latest peer reviewed clinical paper titled "Treatment of Acne with Photopneumatic Therapy," by Tina S. Alster MD et al which is published in the March 2009 issue of the Journal of Drugs and Dermatology. The paper studies the clinical efficacy of Photopneumatic Therapy for the treatment of mild to severe facial acne. "Our study noted greatest improvement in patients with severe acne. We are pleased with treatment outcomes, especially for severe acne," said study co-investigator Dr. Alster. The study was performed using Aesthera's ISOLAZ system, the only FDA cleared device for the treatment of Comedonal and Pustular Acne.

Profusion Skin Therapy for Acne, Skin Rejuvenation and Body Tightening

Aesthera will launch Profusion(TM) - (Pro=Professional and Fusion=Combination) - a breakthrough skin therapy that combines the proven clinical benefits of Photopneumatic light treatments with the delivery of Aesthera's proprietary skincare to symbiotically enhance skin treatment outcomes for acne, skin rejuvenation and body tightening. "Profusion's novel mechanism has tremendous therapeutic potential for innovative new applications. We are very excited about its clinical potential," says Vic Narurkar, MD, Chair of Dermatology at the California Pacific Medical Center (CPMC) in San Francisco, CA. "Profusion Skin Therapy is the fastest growing procedure in our practice. We routinely perform it in combination with the majority of skin treatments we offer," he adds. New applications of the technology include body tightening and skin lightening.

Additionally, Aesthera will release results of a multi-year scientific collaboration with the University of California at Riverside on Profusion Skin Therapy. "Our collaboration with the UC Riverside team reflects our commitment to basing all our treatment solutions on solid science," says Robert Anderson, PhD, Co-Founder and Chief Technical Officer of Aesthera. "We are very excited about expanding the commercial applications of Profusion Skin Therapy and are working on future applications of this novel technology," he added.

Innovative Body Tightening Technology

Moving beyond existing frameworks that address and treat body tightening, shaping and contouring Aesthera will be previewing a revolutionary approach to body tightening technology. The company's innovative body tightening platform (pending FDA clearance) will utilize a unique delivery mechanism and state of the art applicator that allows for high treatment precision and focused energy delivery. The patient benefits of Aesthera's unique solution will be fast, painless, and extremely precise treatments.

"Our continuous development and commercialization of solutions reflects our commitment to growing and strengthening our leadership position in the dermatology market," said Alon Maor, Aesthera's President & CEO.

In addition, to the above launches, Aesthera's technology will be included in over 11 podium presentations by thought leaders in dermatology.

For a complete list of podium presentations, or for more information on Profusion Skin Therapy or Isolaz Light Treatments, visit www.AESTHERA.Com,, call 877.275.4779, or email

About Photopneumatic(TM) Technology

Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

About Aesthera Corporation

Aesthera ( develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology. Clinically proven to be pain-free and up to seven times faster than currently available light-based aesthetic systems, Aesthera's revolutionary systems combine the proven properties of therapeutic light with gentle pneumatic energy to more effectively work on dermal and epidermal skin targets.

    Sarvar Kothavala
    Aesthera Corp.

SOURCE Aesthera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, ... The new Q-Suite 6 platform is based on the latest Java Enterprise standards. By ... piece of software for many key components of the suite. Much of the suite ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna industry, ... far-infrared saunas. , For traditional saunas, Finnleo is offering 20% off ... and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown trees. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: